Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 2/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.34 |
| ▸ | ERN1 | O75460 | 1/20 | 0.32 |
| ▸ | HCRTR1 | O43613 | 9/20 | 0.31 |
| ▸ | HCRTR2 | O43614 | 9/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3797181 | 0.94 | THRB (0.34) | HDAC1HDAC6ERN1HCRTR1HCRTR2 | |
| SCHEMBL3793447 | 0.91 | ERN1 (0.32) | ERN1HCRTR1HCRTR2 | |
| SCHEMBL13228830 | 0.91 | ERN1 (0.32) | ERN1HCRTR1HCRTR2 | |
| SCHEMBL3788865 | 0.91 | HDAC1 (0.35) | HDAC1HDAC6ERN1HCRTR1HCRTR2 | |
| SCHEMBL3792510 | 0.88 | TAS1R3 (0.38) | HDAC1HDAC6 | |
| SCHEMBL3793511 | 0.88 | HDAC1 (0.38) | HDAC1HDAC6ERN1HCRTR1HCRTR2 | |
| SCHEMBL3790994 | 0.87 | HDAC1 (0.34) | HDAC1HDAC6ERN1 | |
| SCHEMBL13228825 | 0.87 | HDAC1 (0.34) | HDAC1HDAC6ERN1 | |
| SCHEMBL3789953 | 0.86 | SCN9A (0.33) | ERN1HCRTR1HCRTR2 | |
| SCHEMBL13228827 | 0.86 | SCN9A (0.33) | ERN1HCRTR1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100204265-A1 | Certain Nitrogen Containing Bicyclic Chemical Entities for Treating Viral Infections | GENELABS TECHNOLOGIES, INC. | 2010-08-12 | — | — | US | claimed |
| US-20100204265-A1 | Certain Nitrogen Containing Bicyclic Chemical Entities for Treating Viral Infections | GENELABS TECHNOLOGIES, INC. | 2010-08-12 | — | — | US | disclosed |
| US-20100204265-A1 | Certain Nitrogen Containing Bicyclic Chemical Entities for Treating Viral Infections | GENELABS TECHNOLOGIES, INC. | 2010-08-12 | — | — | US | disclosed |
| US-20100204265-A1 | Certain Nitrogen Containing Bicyclic Chemical Entities for Treating Viral Infections | GENELABS TECHNOLOGIES, INC. | 2010-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204265-A1 | Certain Nitrogen Containing Bicyclic Chemical Entities for Treating Viral Infections | OAT, HAVCR2, CPS1 | HDAC1 936/4885HDAC6 746/4885ERN1 237/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.